Illumina, Inc. (NASDAQ:ILMN) Short Interest Update

Illumina, Inc. (NASDAQ:ILMN) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 5,040,000 shares, a decline of 22.6% from the December 15th total of 6,510,000 shares. Based on an average daily trading volume, of 2,000,000 shares, the short-interest ratio is currently 2.5 days.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. TD Cowen raised their target price on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Royal Bank of Canada raised their price objective on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Barclays raised their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Robert W. Baird increased their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.

Hedge Funds Weigh In On Illumina

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Empowered Funds LLC raised its stake in Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after acquiring an additional 66 shares in the last quarter. Caprock Group LLC raised its stake in shares of Illumina by 3.0% during the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after purchasing an additional 83 shares in the last quarter. Integrated Advisors Network LLC lifted its holdings in Illumina by 2.0% in the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the period. Moors & Cabot Inc. grew its position in Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after buying an additional 95 shares in the last quarter. Finally, Carson Advisory Inc. increased its stake in Illumina by 3.8% during the 3rd quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock valued at $360,000 after buying an additional 102 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $136.19 on Thursday. Illumina has a 1-year low of $100.08 and a 1-year high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The business’s fifty day moving average price is $140.55 and its two-hundred day moving average price is $133.10.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same period last year, the firm posted $0.33 EPS. Illumina’s quarterly revenue was down 3.5% compared to the same quarter last year. On average, analysts anticipate that Illumina will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.